Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» tirzepatide
tirzepatide
Lilly’s tirzepatide cuts diabetes risk, study data show
BioPharma Dive
Tue, 08/20/24 - 11:54 am
Eli Lilly
tirzepatide
Mounjaro
Zepbound
type 2 diabetes
diabetes
clinical trials
Eli Lilly's weight loss drug tirzepatide gets approval in China
Reuters
Fri, 07/19/24 - 11:45 am
Eli Lilly
tirzepatide
China
Boehringer, Lilly face off in MASH at EASL
Pharmaphorum
Mon, 06/10/24 - 11:14 am
Eli Lilly
Boehringer Ingelheim
MASH
EASL
tirzepatide
survodutide
Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expansion
BioSpace
Wed, 06/5/24 - 11:08 am
Eli Lilly
NASH
MASH
clinical trials
tirzepatide
Lilly wins NICE endorsement for tirzepatide in obesity—with a catch
Fierce Pharma
Tue, 06/4/24 - 11:38 am
Eli Lilly
UK
NICE
tirzepatide
obesity
type 2 diabetes
diabetes
Lilly Suffers Legal Loss in Tirzepatide Case Against Compounding Pharmacy
BioSpace
Fri, 04/12/24 - 11:13 am
Eli Lilly
tirzepatide
legal
compounding pharmacies
Eli Lilly mounts clinical and commercial case for tirzepatide as Mounjaro, Zepbound chalk up major gains
Fierce Pharma
Tue, 02/6/24 - 09:33 am
Eli Lilly
tirzepatide
Novo Nordisk
Zepbound
Mounjaro
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
Motley Fool
Fri, 11/10/23 - 12:19 pm
Eli Lilly
donanemab
tirzepatide
mirikizumab
lebrikizumab
pirtobrutinib
How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets
Medical Marketing and Media
Thu, 11/9/23 - 11:41 pm
Eli Lilly
tirzepatide
weightloss
Zepbound
Mounjaro
Lilly to help BioAge test muscle regeneration therapy in combo with weight loss drug tirzepatide
Fierce Biotech
Thu, 10/26/23 - 10:46 pm
Eli Lilly
BioAge Labs
muscle regeneration
tirzepatide
Mounjaro
BGE-105
Lilly’s Tirzepatide Shows Strong Weight Loss Efficacy in Phase III Study
BioSpace
Mon, 10/16/23 - 10:17 am
Eli Lilly
tirzepatide
weight loss
clinical trials
Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says
Fierce Pharma
Thu, 04/27/23 - 10:48 pm
Eli Lilly
obesity
tirzepatide
patients
Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy
Fierce Pharma
Thu, 10/6/22 - 10:59 am
Eli Lilly
Novo Nordisk
obesity
FDA
fast track
tirzepatide
Eli Lilly touts early demand for high-stakes diabetes launch Mounjaro: analysts
Fierce Pharma
Thu, 09/15/22 - 10:34 am
Eli Lilly
tirzepatide
Mounjaro
diabetes
Lilly's highly anticipated diabetes drug Mounjaro wins FDA blessing
Fierce Pharma
Sun, 05/15/22 - 11:07 pm
Eli Lilly
Mounjaro
tirzepatide
FDA
diabetes
type 2 diabetes
Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity
Fierce Biotech
Thu, 04/28/22 - 10:53 am
Eli Lilly
tirzepatide
obesity
Wegovy
Novo Nordisk
Big pharma’s key second-quarter data
EP Vantage
Tue, 03/29/22 - 10:32 am
Roche
tiragolumab
Giredestrant
Sanofi
Eli Lilly
tirzepatide
Novo Nordisk
GSK
Pfizer
RSV
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one obesity, one diabetes
Fierce Pharma
Wed, 01/12/22 - 11:10 am
JPMHC 2022
Eli Lilly
Dave Ricks
tirzepatide
diabetes
obesity
Pages
1
2
next ›
last »